JWA
CERE

JFS Wealth Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

JFS Wealth Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed -$3K – 1922
2021
Q3 		$3K Buy
+100
New +$2.81K ﹤0.01% 760

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

JFS Wealth Advisors's CERE Position: Q4 2021 in Review

JFS Wealth Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2021, closing a stake of 100 shares — an estimated $3K sold.

JFS Wealth Advisors first reported a position in CERE in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 107 funds tracked by Wall St. Rank hold CERE as of Q4 2021.

  • JFS Wealth Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • JFS Wealth Advisors sold 100 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2021, an estimated $3K.
  • JFS Wealth Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • JFS Wealth Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $3K in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2021.

Based on JFS Wealth Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.